Atlas Trials

Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus

Clinical trial NCT07363512 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07363512
Sponsor
Henan Cancer Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HCC - Hepatocellular Carcinoma
Start date
2026-01-05
Primary completion
2028-03-01
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.